» Articles » PMID: 37781912

Association of Tear Cytokine Ratios with Symptoms and Signs of Dry Eye Disease: Biomarker Data from the Dry Eye Assessment and Management Study

Overview
Journal Curr Eye Res
Publisher Informa Healthcare
Specialty Ophthalmology
Date 2023 Oct 2
PMID 37781912
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To assess the relationship between tear inflammatory cytokine ratios (CRs) and signs and symptoms of dry eye disease (DED) to investigate the possible use of tear CRs, which may better address the complexity of cytokine interactions than absolute cytokine levels, as a DED biomarker.

Methods: Tear concentrations of IL-1b, IL-6, IL-8, IL-10, IL-17A, IFN-g, and TNF-a were measured using standardized procedures, as were DED signs (corneal and conjunctival staining scores, tear break-up time, Schirmer test, Meibomian gland plugging, tear osmolarity, composite sign severity score) and symptoms [Ocular Surface Disease Index (OSDI)]. Ratios between pro-inflammatory (IL-1b, IL-8, IL-17A, IFN-g, and TNF-a) and anti-inflammatory (IL-10) cytokines were calculated. Given its opposing roles in inflammation, IL-6 was tested as both a pro- and anti-inflammatory cytokine. Correlations between CR and DED symptoms and signs were calculated using Spearman correlation coefficients (rho).

Results: At baseline, 131 patients, 80.2% female and mean age 54.2 years (SD 14.1, range 20-82), from 10 sites of the Dry Eye Assessment and Management study had sufficient tear volumes ≥4 μL for analysis. IL-6:IL-10, IL-8:IL-10, and TNF-a:IL-10 had some significant correlations, mostly with conjunctival or corneal staining or the composite sign severity score (IL-8:IL-10 and conjunctival staining: rho = 0.19,  = 0.03; IL-6:IL-10 and corneal staining: rho = 0.31,  < 0.001; IL-8:IL-10 and corneal staining: rho = 0.21,  = 0.01; IL-6:IL-10 and composite sign severity score: rho = 0.26,  = 0.003; IL-8:IL-10 and composite sign severity score: rho = 0.26,  = 0.003; TNF-a:IL-10 and corneal staining: rho = 0.29,  < 0.001; TNF-a:IL-10 and Schirmer test: rho = -0.23,  = 0.009). CRs had no significant correlation with DED symptoms. All significant correlations using IL-6 in the denominator (anti-inflammatory) produced counterintuitive results based on clinical understanding of the disease.

Conclusions: Pro- to anti-inflammatory CR was weakly correlated with some DED signs and not with symptoms, as measured by OSDI. Future studies in different dry eye populations are needed and should address sampling biases and tear collection techniques.

Citing Articles

Longitudinal Analysis of Tear Cytokine Ratios in Association with Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management (DREAM) Study.

Zhao C, Chen Y, Yu Y, Ying G, Asbell P Curr Eye Res. 2024; 50(2):124-131.

PMID: 39267294 PMC: 11774680. DOI: 10.1080/02713683.2024.2398113.


Inflammation mechanism and anti-inflammatory therapy of dry eye.

Chu L, Wang C, Zhou H Front Med (Lausanne). 2024; 11:1307682.

PMID: 38420354 PMC: 10899709. DOI: 10.3389/fmed.2024.1307682.

References
1.
Asbell P, Maguire M, Pistilli M, Ying G, Szczotka-Flynn L, Hardten D . n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. N Engl J Med. 2018; 378(18):1681-1690. PMC: 5952353. DOI: 10.1056/NEJMoa1709691. View

2.
Roy N, Wei Y, Ying G, Maguire M, Asbell P . Association of Tear Cytokine Concentrations with Symptoms and Signs of Dry Eye Disease: Baseline Data from the Dry Eye Assessment and Management (DREAM) Study. Curr Eye Res. 2023; 48(4):339-347. PMC: 10252992. DOI: 10.1080/02713683.2022.2162088. View

3.
McCann P, Abraham A, Mukhopadhyay A, Panagiotopoulou K, Chen H, Rittiphairoj T . Prevalence and Incidence of Dry Eye and Meibomian Gland Dysfunction in the United States: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2022; 140(12):1181-1192. PMC: 9614673. DOI: 10.1001/jamaophthalmol.2022.4394. View

4.
Kany S, Vollrath J, Relja B . Cytokines in Inflammatory Disease. Int J Mol Sci. 2019; 20(23). PMC: 6929211. DOI: 10.3390/ijms20236008. View

5.
Lemp M . Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995; 21(4):221-32. View